Clinical trials: Targeted Therapy
Sarcoma
Advanced MR Imaging in Sarcoma Patients
We intend to investigate the clinical application of two emerging imaging modalities for which the technical capability is currently in place at Mayo Clinic.
- Trial name
- NCT02705391
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Mayo Clinic
Cancers Which Are CD44v6 Positive
4SCAR-CD44v6 T Cell Therapy Targeting Cancer
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of 4SCAR-CD44v6 T-cell therapy targeting multiple cancers.
- Trial name
- NCT04427449
- Testing
- CD44v6-specific CAR gene-engineered T cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Depression, Depressive Disorder
Targeting Adolescent Depressive Symptoms Via Brief, Web-Based Interventions
Major depression (MD) in youth is a serious psychiatric illness with extensive morbidity and mortality. The American Academy of Pediatrics recently released practice guidelines promoting primary care (PC)-based youth MD…
- Conditions
- Depression, Depressive Disorder, Behavioral Symptoms, Mood Disorders
- Trial name
- NCT04066985
- Testing
- Growth Mindset Online Single-Session Program, Self-Kindness Online Single-Session Program, Supportive Therapy Online Single-Session Program (Control)
- Where
- United States
- Volunteers
- 501 people, healthy volunteers welcome
- Sponsor
- Child Mind Institute
Glioblastoma (GBM)
Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening: Advanced Brain Tumor TheRApy Clinical Trial In Patients Scheduled for shOrt Course radiatioN
Patients will receive in addition to standard histology analysis also the PDC- based drug screening.
- Trial name
- ATTRACTION (NCT07627334)
- Testing
- CBmed drug screening platform
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Medical University of Vienna
Cancer
Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis
The primary objective of this study is to verify the safety of antigen-specific T cells (CAR-T) and engineered immune effector cytotoxic T cells (EIE) modified by immunoregulatory genes and immune modified dendritic cell vaccine…
- Trial name
- NCT04085159
- Testing
- Antigen-specific T cells CART/CTL and DCvac
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Malaria, Febrile Illness
Malaria Diagnostic Testing and Conditional Subsidies to Target ACTs in the Retail Sector: TESTsmART Aim 2 - Nigeria
Highly subsidized first-line antimalarials (artemisinin combination therapy or ACT) are available over the counter in the private retail sector in most malaria-endemic countries.
- Trial name
- NCT04428385
- Testing
- Testing incentive, Conditional artemisinin combination therapy subsidy
- Where
- Nigeria
- Volunteers
- 2,205 people
- Sponsor
- Duke University
Lupus Erythematosus, Systemic, Lupus Nephritis
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
The purpose of this study is to evaluate the efficacy, safety and drug levels of CC-97540 in participants with active systemic lupus erythematosus (SLE) including lupus nephritis with inadequate response to glucocorticoids and at…
- Trial name
- NCT07015983
- Testing
- CC-97540, Fludarabine, Cyclophosphamide
- Where
- 97 sites in United States, Argentina and 14 more
- Volunteers
- 89 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Acute Lymphoblastic Leukemia
Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia
This study is a single arm clinical study to observe the safety ，dose tolerance and pharmacokinetic characteristics of CAR NK-CD19 in patients with recurrent or refractory CD19 positive acute lymphoblastic leukemia, and…
- Trial name
- NCT05563545
- Testing
- CAR-NK-CD19 Cells
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
B-Cell Lymphoblastic Leukemia/Lymphoma
CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
This study is a multi-center, open, prospective single-arm clinical study of patients with relapsed / refractory B cell hematological tumors to evaluate the safety and efficacy of CD19 \& CD22 bispecific CAR-T cells in relapsed /…
- Trial name
- NCT06735495
- Testing
- CD19&CD22 bispecific CAR-T cells
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lupus Nephritis, Remission
Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus Nephritis
The goal of this single-center, prospective clinical trial is to test the safety and efficacy of belimumab combined with multi-target therapy in the treatment of severe lupus nephritis.
- Conditions
- Lupus Nephritis, Remission, Safety Issues
- Trial name
- BEAM (NCT05863936)
- Testing
- Methylprednisolone Injectable Suspension, Belimumab Injection, Immunosuppressive Agents
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Nanjing University School of Medicine
Fibrillation, Atrial
Thromboembolic And Bleeding Risks During anticoaGulant trEatment in Asian paTients With Atrial Fibrillation (TARGET-AF)
This study was design to investigate the efficacy and safety of NOAC therapy in Koreans
- Trial name
- NOAC (NCT06874894)
- Where
- 2 sites in South Korea
- Volunteers
- 1,021 people
- Sponsor
- Chung-Ang University Hospital
Impaired Renal Function
Computer Prescribing System and Impaired Renal Function
To evaluate the quality of orders for target drugs in old patients with impaired renal function, hospitalized or living in long stay units, and to improve these practices by means of a counselling system coupled to a computer…
- Trial name
- Ordoclic-IR (NCT00784381)
- Testing
- computer-assisted counselling about target drugs
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Premature Infant, Oxygen Therapy
Servo Controlled Oxygen Targeting Study
Most premature babies require oxygen therapy. There is uncertainty about what oxygen levels are the best. The oxygen levels in the blood are measured using a monitor called a saturation monitor and the oxygen the baby breathes is…
- Conditions
- Premature Infant, Oxygen Therapy, Hypoxia, Hyperoxia
- Trial name
- SCO2T (NCT04177992)
- Testing
- Servo control
- Where
- United Kingdom
- Volunteers
- 22 people
- Sponsor
- University of Edinburgh
Obesity/therapy, Prevention and Control
Cognitive-Behavioral Intervention to Increase Tummy Time Practice and Maintain Healthy Weight in Infants
Childhood obesity is a serious health problem worldwide evidenced by its high prevalence, specifically for the age group called the first 1000 days of life.
- Trial name
- NCT06616467
- Testing
- Tummy Time for the prevention of childhood obesity
- Where
- Mexico
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Universidad Autonoma de Nuevo Leon
Breast Cancer
Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer
The goal of this clinical research study is to learn if Tarceva® (erlotinib hydrochloride) can help control triple receptor-negative breast cancer. The safety of this drug will also be studied.
- Trial name
- NCT00739063
- Testing
- Tarceva
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Insomnia, Suicidal Ideation
Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior
This study will test the effectiveness of a sleep-related primary suicide prevention program entitled TAILOR (Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior), which includes specific behavior-change…
- Conditions
- Insomnia, Suicidal Ideation, Suicide, Attempted
- Trial name
- TAILOR (NCT05390918)
- Testing
- TAILOR, Enhanced Usual Care
- Where
- United States
- Volunteers
- 235 people
- Sponsor
- Jeff Bridge
Hematologic Neoplasms, Gram-Negative Bacterial Infections
Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients
This is a prospective, single-arm, observational, exploratory clinical study to evaluate whether the standard fixed dose of ceftazidime-avibactam (CAZ-AVI) achieves sufficient drug exposure (pharmacokinetic/pharmacodynamic, or…
- Conditions
- Hematologic Neoplasms, Gram-Negative Bacterial Infections, Pseudomonas Aeruginosa Infection, Klebsiella Pneumoniae Infections
- Trial name
- CZA-TDM (NCT07703644)
- Testing
- Ceftazidime-avibactam, Therapeutic Drug Monitoring (TDM) and Microbiological Surveillance
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sizhou Feng
Renal Cell Carcinoma (Kidney Cancer), Immunotherapy
Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial
This phase II, multicenter, single-arm, open-label study evaluates first-line ipilimumab N01 plus sintilimab and lenvatinib in patients with locally advanced or metastatic TFE3-rearranged renal cell carcinoma (TFE3-rRCC), a rare…
- Conditions
- Renal Cell Carcinoma (Kidney Cancer), Immunotherapy, Molecular Targeted Therapy
- Trial name
- NCT07715565
- Testing
- Ipilimumab Injection, Sintilimab injection, Lenvatinib
- Where
- China
- Volunteers
- 66 people
- Sponsor
- West China Hospital
Angioplasty, Critical Lower Limb Ischemia
Outcomes of Straight-line Flow Versus Angiosome-targeted Angioplasty in Treatment of Critical Lower Limb Ischemia
Peripheral arterial disease (PAD) affects more than 200 million people worldwide. Although over 50% are asymptomatic, it accounts for 4% of all amputations.
- Trial name
- NCT06127134
- Testing
- peripheral angioplasty for tibial vessels
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Kafrelsheikh University
Relapsed or Refractory Pediatric Tumor
Proof -of -Concept Study To Stratify Targeted Therapies Adapted To Molecular Profiling
In the light of the development of high-throughput technologies enabling a biology-based reclassification of tumors and the increasing number of available specifically targeting anticancer agents the era of "precision medicine"…
- Trial name
- MAPPYACTS (NCT02613962)
- Testing
- biopsy or surgical resection of tumor and blood sampling
- Where
- 5 sites in France, Ireland and 3 more
- Volunteers
- 791 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris